Colorectal Cancer Update, Issue 1, 2018


Alan P Venook, MD

Track 1: IDEA pooled analysis: Duration of adjuvant oxaliplatin-based chemotherapy for Stage III colon cancer
Track 2: Identification of patients to receive longer versus shorter duration of adjuvant chemotherapy
Track 3: Use of CAPOX versus FOLFOX adjuvant regimens
Track 4: Prognostic and predictive value of primary tumor sidedness
Track 5: Intestinal microbiota and colorectal cancer (CRC)
Track 6: Treatment approach for BRAF V600E-mutated metastatic CRC (mCRC)
Track 7: Prolonged response to T-DM1 in a patient with rapidly progressive HER2-amplified mCRC
Track 8: EGFR tyrosine kinase inhibitors in patients with HER2-mutated mCRC
Track 9: Effects of diet and lifestyle on outcome in colon cancer
Track 10: Recommendations for vitamin D supplementation
Track 11: Counseling patients about increased physical activity
Track 12: Case: A 46-year-old man with right-sided primary MLH1-deficient cecal cancer and bulky nodal disease receives FOLFOXIRI/bevacizumab but discontinues because of toxicity and is switched to pembrolizumab
Track 13: Rates of response and prolonged disease control with immune checkpoint inhibitors in mCRC
Track 14: Biomarkers for predicting the effectiveness of anti-PD-1/PD-L1 checkpoint inhibitors in mCRC
Track 15: Spectrum of toxicities associated with anti-PD-1/PD-L1 checkpoint inhibitors
Track 16: Phenotypes of microsatellite instability (MSI)-high colon cancer
Track 17: Case: A 65-year-old man with multiple recurrences of mCRC receives regorafenib followed by TAS-102
Track 18: Dosing and tolerability of regorafenib
Track 19: Regorafenib-associated tumor cavitation
Track 20: Sequencing regorafenib and TAS-102 as later-line therapy
Track 21: TAS-102-associated neutropenia
Track 22: California End-of-Life Option Act and aid-in-dying medication
Track 23: Case: A 66-year-old man undergoes simultaneous resection of primary sigmoid cancer and a solitary liver metastasis followed by pseudoadjuvant therapy with FOLFOX
Track 24: Investigational combination strategies for microsatellite-stable (MSS) mCRC

Scott Kopetz, MD, PhD

Track 1: CheckMate 142: Activity of nivolumab in patients with MSI-high mCRC
Track 2: Dosing schedules and choosing between anti-PD-1/PD-L1 checkpoint inhibitors for mCRC
Track 3: Incidence of high MSI in other cancers: Implications for testing
Track 4: Pros and cons of MSI testing methods
Track 5: First-line treatment with anti-PD-1/PD-L1 checkpoint inhibitors in mCRC
Track 6: Clinical characterization of MSI-high CRC
Track 7: Reliability in assessment of MSI status after chemotherapy
Track 8: Investigation of predictive biomarkers for anti-PD-1/PD-L1 checkpoint inhibition in mCRC
Track 9: Relationship between mutational load and response to anti-PD-1/PD-L1 checkpoint inhibitors
Track 10: Role of the gut microbiome in the pathogenesis of colon cancer and response to checkpoint inhibitors
Track 11: Rapidity of response to checkpoint inhibitors in patients with MSI-high tumors
Track 12: Neoadjuvant studies of checkpoint inhibitors in MSI-high colon cancer
Track 13: Combination strategies with checkpoint inhibitors for MSS mCRC
Track 14: Pseudoprogression with checkpoint inhibitors
Track 15: Consensus molecular subtypes in colon cancer
Track 16: Prediction of treatment benefit among molecular subtypes
Track 17: Case: A 67-year-old woman with BRAF V600E-mutated mCRC enrolls on the SWOG-S1406 clinical trial of irinotecan/cetuximab with or without vemurafenib
Track 18: Utility of liquid biopsies in mCRC
Track 19: Efficacy and tolerability of irinotecan/cetuximab/vemurafenib
Track 20: Influence of side-effect profiles in sequencing regorafenib and TAS-102
Track 21: Case: A 52-year-old man with mCRC is found to have HER2 amplification and responds to trastuzumab/pertuzumab
Track 22: Activity of T-DM1 in HER2-amplifed mCRC
Track 23: Multiplex testing for patients with mCRC

Zev Wainberg, MD, MSc

Track 1: Case: A 68-year-old man with resected right-sided primary BRAF V600E-mutated, MSI-high mCRC and disease progression on FOLFOX/bevacizumab and FOLFIRI experiences a 2-year response to nivolumab
Track 2: Targeted therapy for BRAF-mutated mCRC
Track 3: Emergence of checkpoint inhibitors as treatment options for MSI-high mCRC
Track 4: Tolerability of checkpoint inhibitors in gastrointestinal cancers
Track 5: Treatment duration and scheduling of checkpoint inhibitors
Track 6: Novel research strategies with checkpoint inhibitors in CRC
Track 7: Gastrointestinal microbiome and new drug development
Track 8: Treatment of MSI-high mCRC that progresses on checkpoint inhibitor therapy
Track 9: TAS-102 after disease progression on standard fluoropyrimidine, oxaliplatin and irinotecan-based regimens
Track 10: Dose reductions for TAS-102-related cytopenia
Track 11: Initial dosing of regorafenib
Track 12: RAS testing in colon cancer
Track 13: RAS oncogene in the pathogenesis of colon and other cancers
Track 14: Oncogene addiction in BRAF-mutated colon cancer compared to other solid tumors
Track 15: Efforts to develop KRAS-targeted agents
Track 16: Case: A 55-year-old woman with moderately differentiated N1 colon cancer and 2 of 24 positive lymph nodes receives 3 months of adjuvant FOLFOX
Track 17: Degree of benefit needed for patients to undergo adjuvant chemotherapy
Track 18: Counseling patients about adjuvant chemotherapy

Howard S Hochster, MD

Track 1: Case: A 58-year-old man with T3N1 sigmoid colon cancer receives 3 months of adjuvant CAPOX
Track 2: SWOG-S1613: A Phase II study comparing pertuzumab/trastuzumab to cetuximab/irinotecan for HER2-amplified mCRC
Track 3: STEAM Phase II trial results: Sequential or concurrent FOLFOXIRI/bevacizumab versus FOLFOX/bevacizumab as first-line treatment of mCRC
Track 4: FOLFOXIRI/bevacizumab for BRAF-mutated mCRC
Track 5: Onset and delayed recovery of neutropenia as an indicator of response to TAS-102
Track 6: Ongoing studies combining TAS-102 with other agents in earlier disease settings
Track 7: Case: A 52-year-old man with refractory mCRC receives TAS-102, bevacizumab and irinotecan on a clinical trial
Track 8: Considerations in sequencing TAS-102 and regorafenib
Track 9: CALGB/SWOG-80405: Relationship among somatic DNA mutations, MSI status, mutational load and survival in mCRC
Track 10: Potential rationale for the efficacy of atezolizumab/bevacizumab in MSI-high mCRC
Track 11: Incidence of MSI-high tumors in mCRC
Track 12: Ongoing Phase III studies of anti-PD-1/PD-L1 checkpoint inhibitors as first-line therapy for mCRC
Track 13: Case: A 40-year-old man with metastatic rectal cancer and Lynch syndrome receives atezolizumab/bevacizumab on a clinical trial
Track 14: Anti-PD-1/PD-L1 checkpoint inhibitor-associated immune-related adverse events
Track 15: Perspective on hyperthermic intraperitoneal chemotherapy
Track 16: Ongoing Alliance A021502 Phase III study of adjuvant chemotherapy alone or with atezolizumab for Stage III colon cancer with deficient DNA mismatch repair
Track 17: Case: A 48-year-old woman with BRAF V600E-mutated mCRC initially receives FOLFIRINOX followed by cetuximab/encorafenib on a clinical trial
Track 18: High mutational burden in patients with BRAF mutations
Track 19: SWOG-S1406: Results of a Phase II trial of irinotecan/cetuximab with or without vemurafenib for BRAF-mutated mCRC
Track 20: Preliminary results of the Phase III BEACON study evaluating cetuximab, encorafenib and binimetinib combination therapy for BRAF V600E-mutated mCRC
Track 21: COTEZO IMblaze 370: A Phase III study of atezolizumab with or without cobimetinib versus regorafenib for previously treated MSS mCRC
 
FACULTY
 
Alan P Venook, MD
Professor of Clinical Medicine
University of California, San Francisco
San Francisco, California
 
Scott Kopetz, MD, PhD
Associate Professor
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
 
Zev Wainberg, MD, MSc
Associate Professor
Department of Medicine
Director
Early Phase Clinical Research Support
Co-Director, UCLA GI Oncology Program
Jonsson Comprehensive Cancer Center
Los Angeles, California
 
Howard S Hochster, MD
Associate Director (Clinical Research)
Yale Cancer Center
Professor of Medicine
Yale School of Medicine
New Haven, Connecticut
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida